-
-
-
-
-
-
-
-
Compounds IC50 μmol/L CC50 μmol/L Homoharringtonine 0.19 50.66 Bruceine D 0.36 25.66 Cucurbitacin B 0.26 15.66 Dihydroartemisinin 0.47 > 100 Digitonin 0.62 > 100 Plumbagin 0.41 12.56 Schizandrin A 0.42 21.53 Dihydrochelerythrine 0.49 > 100 Betulonic acid 0.52 44.54 Artesunate 0.57 > 100 Sodium aescinate 0.69 > 100 Escin 0.76 > 100 Oleanonic acid 1.99 32.61 Cepharanthine 2.25 29.85 Corosolic acid 2.62 9.99 Bergamotine 2.98 23.76 Harringtonine 3.02 21.34 Schisanhenol 3.02 21.34 Fangchinoline 3.78 38.58 Fangchinoline 4.39 40.10 Dihydroactinidiolide 4.66 > 100 Schizandrin B 6.00 41.18 Tetrandrine 6.37 19.35 Liriope muscari baily saponins C 7.78 28.32 Ophiopogonin D 7.78 28.32 Saikosaponin A 9.22 27.72 Berbamine dihydrochloride 9.79 40.32 Daurisoline 10.13 29.28 Reserpine 10.20 33.33 Curcumin 11.23 > 100 Magnolol 31.37 > 100 After primary HTS, 31 compounds were selected for follow-up analysis. Each compound was used to pre-treat cells at concentrations of 0.1 μmol/L, 0.25 μmol/L, 0.5 μmol/L, 1 μmol/L, 2 μmol/L, 4 μmol/L, 10 μmol/L and 100 μmol/L. The vehicle was used as negative control. After 48 h of infection, cell nuclei were stained with Hoechst. Then the plates were scanned by using a high-contentscreening microplate imaging reader. Fifty nine fields per well were scanned using 209 objective and analysed for percentage of infection and cell number. The infection positive cell rates and total cell counts were all normalized to that of vehicle control wells. Table 1. Evaluation of the primary HTS selected compounds.
Figure 7 个
Table 1 个